Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

被引：16

作者：

von Tresckow, Bastian ^{[1
,2
]}

Fanale, Michelle ^{[3
,13
]}

Ardeshna, Kirit M. ^{[4
]}

Chen, Robert ^{[5
]}

Meissner, Julia ^{[6
]}

Morschhauser, Franck ^{[7
]}

Moskowitz, Craig ^{[8
,14
]}

Zinzani, Pier Luigi ^{[9
]}

Giezek, Hilde ^{[10
]}

Balakumaran, Arun ^{[11
]}

Vo, Thao T. ^{[11
]}

Raut, Monika ^{[11
]}

Brice, Pauline ^{[12
]}

机构：

[1] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany

[2] Univ Hosp Cologne, Cologne, Germany

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[4] Univ Coll London Hosp, London, England

[5] City Hope Natl Med Ctr, Dept Hematol, 1500 E Duarte Rd, Duarte, CA 91010 USA

[6] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[7] CHRU Lille, Hop Claude Huriez, Lille, France

[8] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[9] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[10] MSD, Brussels, Belgium

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Hop St Louis, AP HP, Dept Hematol, Paris, France

[13] Seattle Genet, Bothell, WA USA

[14] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 11期

关键词：

Classical Hodgkin lymphoma; health-related quality-of-life; KEYNOTE-087; patient-reported outcomes; pembrolizumab; CANCER; PD-L1; EQ-5D; EORTC;

D O I：

10.1080/10428194.2019.1602262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were >= 90% at week 12 and >= 70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts.

引用

页码：2705 / 2711

页数：7

共 50 条

[21] Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
Choueiri, Toni K.
Tomczak, Piotr
Park, Se Hoon
Venugopal, Balaji
Symeonides, Stefan
Hajek, Jaroslav
Ferguson, Thomas
Chang, Yen-Hwa
Lee, Jae Lyun
Haas, Naomi
Sawrycki, Piotr
Sarwar, Naveed
Gross-Goupil, Marine
Thiery-Vuillemin, Antoine
Mahave, Mauricio
Kimura, Go
Perini, Rodolfo F.
Saretsky, Todd L.
Bhattacharya, Rituparna
Xu, Lei
Powles, Thomas
ONCOLOGIST, 2024, 29 (02): : 142 - 150
[22] Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell Non-Hodgkin Lymphoma (iNHL)
Dreyling, M. H.
Viardot, A.
Salles, G.
Wagner-Johnston, N. D.
Kahl, B. S.
De Vos, S.
Schuster, S. J.
Jurczak, W.
Flinn, I. W.
Flowers, C.
Martin, P.
Blum, K. A.
Davies, A. J.
Zinzani, P. L.
Wagner, L., I
Gopal, A. K.
Ruppert, S.
Kroenig, H.
Schuster, A.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 185 - 185
[23] Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-hodgkin lymphoma (iNHL)
Davies, A.
Salles, G.
Wagner-Johnston, N.
Kahl, B.
De Vos, S.
Schuster, S.
Jurczak, W.
Flinn, I.
Flowers, C.
Martin, P.
Viardot, A.
Blum, K.
Zinzani, P.
Dreyling, M.
Wagner, L.
Li, D.
Godfrey, W.
Gopal, A.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 54 - 54
[24] PATIENT-REPORTED OUTCOMES DATA FROM A PHASE 2 STUDY OF IDELALISIB IN PATIENTS WITH REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (INHL)
Salles, G.
Wagner-Johnston, N. D.
Kahl, B. S.
De Vos, S.
Schuster, S. J.
Jurczak, W.
Flinn, I. W.
Flowers, C.
Martin, P.
Viardot, A.
Blum, K. A.
Davies, A. J.
Zinzani, P. L.
Dreyling, M. H.
Wagner, L. I.
Li, D.
Godfrey, W. R.
Gopal, A. K.
HAEMATOLOGICA, 2014, 99 : 143 - 143
[25] Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Henderson, Tara O.
Castellino, Sharon M.
Keller, Frank G.
Kelly, Kara M.
Curtis, Rachael
Conti, Rena M.
Parsons, Susan K.
BLOOD, 2016, 128 (22)
[26] Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
Chen, Robert
Allibone, Suzanne
Bartlett, Nancy L.
Brice, Pauline
Chen, Andy
Pose, Katrina
Rich, Lynn
Bonthapally, Vijay
Garfin, Phillip M.
Fanale, Michelle
ONCOTARGETS AND THERAPY, 2016, 9 : 2027 - 2034
[27] Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study
Fanale, M. A.
Kline, J.
Chen, R.
Ribrag, V.
Salles, G.
Matsumura, I.
Zhu, Y.
Ricart, A. D.
Balakumaran, A.
Zinzani, P. L.
ANNALS OF ONCOLOGY, 2016, 27
[28] Patient-Reported Outcomes After Chest Radiation for Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL)
Hill-Kayser, C. E.
Vachani, C.
Hampshire, M.
Di Lullo, G.
Metz, J. M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S717 - S718
[29] KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY
Vinti, Luciana
Daw, Stephen
Alvarez, Constantino Sabado
Fagioli, Franca
Beishuizen, Auke
Michel, Gerard
Moleti, Maria Luisa
Cepelova, Michaela
Thorwarth, Anne
Rigaud, Charlotte
De Sabando, Diego Plaza Lopez
Parker, Judith Landman
Zhu, Ying
Pillai, Pallavi
Nahar, Akash
Mauz-Koerholz, Christine
PEDIATRIC BLOOD & CANCER, 2022, 69
[30] Patient-reported outcomes in a phase II study of alectinib
Ohe, Yuichiro
ESMO OPEN, 2018, 3 (05)

← 1 2 3 4 5 →